Life science
REAL-WORLD DATA
COLLECTION
Monsenso enables the remote collection of patient-
generated data and device-generated data from
clinical, post-approval to real-world studies.
Real-World Evidence generation
Monsenso enables real-world evidence (RWE) generation through patient-generated & device-generated data collection across the product life cycle.
Clinical Development
Enable patient-centred drug development with our solutions to impact outcomes that matter to patients. Our solutions are developed with and for patients with mental health and psychiatric conditions to reduce their burden of contributing to research.
Post-Market Studies
Equip global, multi-centre, non-interventional, longitudinal studies with our solutions to measure safety and efficacy, describe patient, drug use, and clinical development across treatment pathways in real-world medical and clinical practice for regulators.
Companion Products
Engage patients with our solutions to enable personalised care, education, self-management, behavioral change, symptom and disease progression monitoring, and medication adherence. Demonstrate value to patients, prescribing physicians and payers.
Clinical Development
Enable patient-centred drug development with our solutions to impact outcomes that matter to patients. Our solutions are developed with and for patients with mental health and psychiatric conditions to reduce their burden and contribute to research.
Clinical Development
Our experience on how we co-created with patients with psychiatric needs & KOLs. Highlight TAs that our targets are working on (Schizophrenia, Bipolar, MDD).How did we help - cheaper, better, faster?
Value: How do we enable patients to share their journey with us - active and passive. Potential to complement RCTs.
Post-Market Studies
Equip global, multi-centre, non-interventional, longitudinal studies with our solutions to measure safety and efficacy, describe patient, drug use, and clinical development across treatment pathways in real-world medical and clinical practice for regulators.
Post-Market Studies
Janssen & Monsenso partnered on a digital solution as part of collecting real-world data from patients. This solution enable real-time monitoring of symptoms and endpoints that reflect safety and effectiveness as part of mandatory survey.
Companion Products
Engage patients with our solutions to enable personalised care, education, self-management, behavioral change, symptom and disease progression monitoring, and medication adherence. Demonstrate value to patients, prescribing physicians and payers.
Companion Products
Our experience with Janssen using OMW + Abilify, Otsuka/Lundbeck? Value demonstration to get clinician buy in.How did we help - cheaper, better, faster?
Value: How can these patient-generated data contribute to payer’s value-based reimbursements?
Digital Biomarkers, Digital Therapeutics & Personalised Medicine
Enhance the development and validation of digital endpoints, biomarkers, therapeutics, and pharmacogenomics testing in the real-world setting using our capabilities for continuous stream of active and passive patient data capture.
HOW OUR SOLUTION SUPPORT REAL-WORLD STUDIES
eConsent
Enables participants to understand the study and their role, and provide informed consent to take part remotely.
ePRO
Track participant data using clinical questionnaires, eDiary, Ecological Momentary Assessments together with sensor based data and data on usage-patterns.
Visualisation and feedback
Improve protocol compliance by providing trial participants visualisations of their progress and motivational feedback.
Direct messaging
Provide timely support to participants remotely, reducing the number of unplanned site visits and potential dropouts.
Medication reminders
Provide patients with information on their medication and reminders to promote adherence.
Protocol Reminders
To ensure protocol compliance, study participants receive notifications and reminders to complete study tasks and site visit.
Patient engagement tools
Engage trial participants through challenges, tools and psychoeducational materials to promote treatment compliance and reduce drop-outs.
Platform integration
Based on open standards allowing to integrate with a wide range of data sources, such as connected devices, wearables, and phone sensors.
Easy recruitment
Send screening questionnaires, invite trial participants remotely with customised study information and assign trial participants to groups and protocols.
eConsent
Enables participants to understand the study and their role, and provide informed consent to take part remotely
Investigator forms
Records HCP/ investigator notes or observations throughout the study (coming soon)
Direct messaging
Provide timely support to participants remotely, reducing the number of unplanned site visits and potential dropouts.
Site dashboard and Visualization
See individual trail participant adherence to the study plan and get insights into health outcomes through historical aggregation of health and behavioural data.
Audit trail
Get full traceability of the "who", "what" "when" and "where" during your studies (coming soon).
Platform integration
Based on open standards that allow integration with a variety of data sources, such as connected devices, wearables, and phone sensors.
Real-world data capture
While RCTs are critical to determining the safety and efficacy of a treatment in a defined population within a controlled design, the usage, safety, and efficacy of the treatment within a more heterogeneous population in the real world remains to be demonstrated to regulators[1] and payers[2].
Our solution
Our platform empowers RWE generation by remotely capturing patient-generated and device-generated data across the product lifecycle on patient safety, quality of life, and functional outcomes that are critical to regulators and payers.
Value-based agreements
As value-based contracting becomes more prevalent, especially for expensive and prevalent mental health conditions, understanding the value of drugs to patients is crucial. Most EHRs lack patient-reported outcomes on symptoms, functions, treatment adherence, and quality of life, missing critical information from the patient’s perspective[3] that could demonstrate the success and value of a treatment[4].
Our solution
By remotely capturing patient-reported outcomes on symptoms, functions, treatment adherence and quality of life in real-world settings, our platform enables Life Sciences companies to demonstrate the value of their drugs to patients in a transparent way to payers and providers.
Medication adherence
About half of patients with major psychiatric conditions such as schizophrenia, major depressive disorder, and bipolar disorder do not adhere to their medications[4]. This delays recovery, increases the risk of hospitalisations and length of hospital stays, costing billions to payers[5].
Our solution
Our digital companion solution provides patients with information on their medication, reminds them to take their medications, and guides them along with their treatment plan to promote adherence and recovery.
New drug launches
About 2/3 of new drugs fall short of sales expectations in their first year on the market1. Nearly half of these launches failed due to a lack of understanding of treatment, responders or the types of HCPs who would be high or low prescribers for the new drug, or an underestimation of the difficulty to convert patients and HCPs from existing treatments, especially when generics are available[6].
Our solution
Our digital companion solution enables remote patient monitoring to identify treatment responders, educate clinicians and patients about the new drug, and demonstrate its value based on real-world, patient-generated data on quality of life and functional outcomes.